Small Intestinal Bacterial Overgrowth: Difference between revisions

From MicrobeWiki, the student-edited microbiology resource
Line 37: Line 37:
Other strategies for management besides eliminating overgrowth include treating underlying conditions that caused overgrowth and addressing nutritional deficiencies potentially caused by SIBO. <ref name="Sachdev"></ref>
Other strategies for management besides eliminating overgrowth include treating underlying conditions that caused overgrowth and addressing nutritional deficiencies potentially caused by SIBO. <ref name="Sachdev"></ref>


Research also proposes dietary changes to help relieve the functional gastrointestinal (GI) symptoms. <ref name="Gibson"> [https://doi.org/10.1038/ajg.2012.49. Gibson, Peter R, and Susan J Shepherd. “Food Choice as a Key Management Strategy for Functional Gastrointestinal Symptoms.” American Journal of Gastroenterology, vol. 107, no. 5, 2012, pp. 657–666., https://doi.org/10.1038/ajg.2012.49. ] </ref> Reduce intake of FODMAPs (fermentable oligo-, di-, and mono-saccharides and polyols)—poorly absorbed short-chain carbohydrates can effectively reduce bloating and other functional gastrointestinal symptoms. <ref name=”Gibson”></ref> Although the effectiveness of this strategy—previously used only to treat IBS and other GI conditions—for treating SIBO-related symptoms is still unclear.  
Research also proposes dietary changes to help relieve the functional gastrointestinal (GI) symptoms. <ref name="Gibson"> [https://doi.org/10.1038/ajg.2012.49. Gibson, Peter R, and Susan J Shepherd. “Food Choice as a Key Management Strategy for Functional Gastrointestinal Symptoms.” American Journal of Gastroenterology, vol. 107, no. 5, 2012, pp. 657–666., https://doi.org/10.1038/ajg.2012.49. ] </ref> Reduce intake of FODMAPs (fermentable oligo-, di-, and mono-saccharides and polyols)—poorly absorbed short-chain carbohydrates can effectively reduce bloating and other functional gastrointestinal symptoms. <ref name="Gibson"></ref> Although the effectiveness of this strategy—previously used only to treat IBS and other GI conditions—for treating SIBO-related symptoms is still unclear.  
<ref name=”Adike”>[https://doi.org/10.1016/j.gtc.2017.09.008 Adike, Abimbola, and John K. DiBaise. “Small Intestinal Bacterial Overgrowth.” Gastroenterology Clinics of North America, vol. 47, no. 1, 2018, pp. 193–208., https://doi.org/10.1016/j.gtc.2017.09.008.] </ref> Other food sources of functional gastrointestinal symptoms including gluten and natural and added food chemicals such as amines and glutamates and the benefit of dietary strategies that reduce the intake of these chemicals are still being researched. <ref name=”Gibson”></ref>
<ref name=”Adike”>[https://doi.org/10.1016/j.gtc.2017.09.008 Adike, Abimbola, and John K. DiBaise. “Small Intestinal Bacterial Overgrowth.” Gastroenterology Clinics of North America, vol. 47, no. 1, 2018, pp. 193–208., https://doi.org/10.1016/j.gtc.2017.09.008.] </ref> Other food sources of functional gastrointestinal symptoms including gluten and natural and added food chemicals such as amines and glutamates and the benefit of dietary strategies that reduce the intake of these chemicals are still being researched. <ref name="Gibson"></ref>


==Interactions Between SIBO and Other Systemic Conditions==
==Interactions Between SIBO and Other Systemic Conditions==

Revision as of 23:18, 7 December 2022

Overview

Small intestinal bacterial overgrowth (SIBO) is defined as the abnormal increase in the overall bacterial population in the small intestine. [1][2] Common symptoms of SIBO include diarrhea, flatulence, abdominal pain and bloating. [1][3][4]Currently there is no single valid test for SIBO, but common ways of screening for SIBO include small-bowel aspiration and quantitative culture and breath testing. [3][5]

SIBO was first suggested by Barker and Hummel in their 1939 publication “Macrocytic anemia in association with intestinal strictures and anastomoses.”, which provides key findings for both the study of Macrocytic anemia and the study of SIBO. [6]





The hypothesis of SIBO and potential detrimental outcomes relevant to children in low-income countries.[1].


At right is a sample image insertion. It works for any image uploaded anywhere to MicrobeWiki. The insertion code consists of:
Double brackets: [[
Filename: PHIL_1181_lores.jpg
Thumbnail status: |thumb|
Pixel size: |300px|
Placement on page: |right|
Legend/credit: Electron micrograph of the Ebola Zaire virus. This was the first photo ever taken of the virus, on 10/13/1976. By Dr. F.A. Murphy, now at U.C. Davis, then at the CDC.
Closed double brackets: ]]

Other examples:
Bold
Italic
Subscript: H2O
Superscript: Fe3+



Testing for SIBO

Medical Management of SIBO

Unfortunately, the current management of SIBO is unclear and mostly empirical. [4][7] Common management strategies include using antibiotics and probiotics.Cite error: Invalid <ref> tag; invalid names, e.g. too many[8]

Other strategies for management besides eliminating overgrowth include treating underlying conditions that caused overgrowth and addressing nutritional deficiencies potentially caused by SIBO. [3]

Research also proposes dietary changes to help relieve the functional gastrointestinal (GI) symptoms. [9] Reduce intake of FODMAPs (fermentable oligo-, di-, and mono-saccharides and polyols)—poorly absorbed short-chain carbohydrates can effectively reduce bloating and other functional gastrointestinal symptoms. [9] Although the effectiveness of this strategy—previously used only to treat IBS and other GI conditions—for treating SIBO-related symptoms is still unclear. [10] Other food sources of functional gastrointestinal symptoms including gluten and natural and added food chemicals such as amines and glutamates and the benefit of dietary strategies that reduce the intake of these chemicals are still being researched. [9]

Interactions Between SIBO and Other Systemic Conditions

Although the prevalence and role in the pathogenesis of other diseases remain uncertain, reviews and case studies still show potential connections between SIBO and other systemic conditions such as irritable bowel syndrome(IBS) or Ehlers-Danlos Syndrome. [2] Other conditions that are hypothesized to be associated with SIBO include cirrhosis, chronic pancreatitis, and celiac disease. [4]

Ehlers-Danlos Syndrome is a group of rare disorders caused by collagen synthesis defects. [11] Delayed gastric emptying, which is a risk factor for SIBO, is common among EDS patients. [4][12][13] Studies show that SIBO diagnosis is common among EDS patients. [12] Another study suggests that EDS might be correlated with the constipation predominant type of SIBO instead of the diarrhea predominant type. [14] Yet because EDS is quite rare among the general population, sample sizes are small for most researches done on EDS patients, especially those involving other comorbidities, which limits the scope of research.[11][14]

Conclusion

Overall text length (all text sections) should be at least 1,000 words (before counting references), with at least 2 images.

Include at least 5 references under References section.

References

  1. ↑ 1.0 1.1 “Small Intestinal Bacterial Overgrowth (SIBO).” Mayo Clinic, Mayo Foundation for Medical Education and Research, 6 Jan. 2022, https://www.mayoclinic.org/diseases-conditions/small-intestinal-bacterial-overgrowth/symptoms-causes/syc-20370168.
  2. ↑ 2.0 2.1 Adike, Abimbola, and John K. DiBaise. “Small Intestinal Bacterial Overgrowth.” Gastroenterology Clinics of North America, vol. 47, no. 1, 2018, pp. 193–208., https://doi.org/10.1016/j.gtc.2017.09.008.
  3. ↑ 3.0 3.1 3.2 Sachdev, Amit H, and Mark Pimentel. “Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance.” Therapeutic advances in chronic disease vol. 4,5 (2013): 223-31. doi:10.1177/2040622313496126
  4. ↑ 4.0 4.1 4.2 4.3 Bohm, Matthew, et al. “Diagnosis and Management of Small Intestinal Bacterial Overgrowth.” Nutrition in Clinical Practice, vol. 28, no. 3, 2013, pp. 289–299., https://doi.org/10.1177/0884533613485882.
  5. ↑ Saad, Richard J., and William D. Chey. “Breath Testing for Small Intestinal Bacterial Overgrowth: Maximizing Test Accuracy.” Clinical Gastroenterology and Hepatology, vol. 12, no. 12, 2014, pp. 1964–1972., https://doi.org/10.1016/j.cgh.2013.09.055
  6. ↑ Barker, W. H., and L. E. Hummel. "Macrocytic anemia in association with intestinal strictures and anastomoses." Bull Johns Hopkins Hosp 64.2 (1939): 15.
  7. ↑ Leonello, R., et al. “P.12.7 Outcome of Patients with Positive Breath Test for SIBO Six Months after Combined Treatment with Rifaximin and Probiotics.” Digestive and Liver Disease, vol. 48, 2016, https://doi.org/10.1016/s1590-8658(16)30289-4
  8. ↑ Richard, Nicolas, et al. “The Effectiveness of Rotating versus Single Course Antibiotics for Small Intestinal Bacterial Overgrowth.” United European Gastroenterology Journal, vol. 9, no. 6, 2021, pp. 645–654., https://doi.org/10.1002/ueg2.12116
  9. ↑ 9.0 9.1 9.2 Gibson, Peter R, and Susan J Shepherd. “Food Choice as a Key Management Strategy for Functional Gastrointestinal Symptoms.” American Journal of Gastroenterology, vol. 107, no. 5, 2012, pp. 657–666., https://doi.org/10.1038/ajg.2012.49.
  10. ↑ Adike, Abimbola, and John K. DiBaise. “Small Intestinal Bacterial Overgrowth.” Gastroenterology Clinics of North America, vol. 47, no. 1, 2018, pp. 193–208., https://doi.org/10.1016/j.gtc.2017.09.008.
  11. ↑ 11.0 11.1 “Ehlers-Danlos Syndrome: Medlineplus Genetics.” MedlinePlus, U.S. National Library of Medicine, https://medlineplus.gov/genetics/condition/ehlers-danlos-syndrome/#frequency.
  12. ↑ 12.0 12.1 Xiong, Tingting, et al. “1182 Small Intestinal Bacterial Overgrowth (SIBO) Is Common in Patients with Ehlers-Danlos Syndrome (EDS).” American Journal of Gastroenterology, vol. 114, no. 1, 2019, https://doi.org/10.14309/01.ajg.0000594256.00026.1d
  13. ↑ Nelson, A. D., et al. “Ehlers Danlos Syndrome and Gastrointestinal Manifestations: A 20-Year Experience at Mayo Clinic.” Neurogastroenterology & Motility, vol. 27, no. 11, 2015, pp. 1657–1666., https://doi.org/10.1111/nmo.12665
  14. ↑ 14.0 14.1 Zhou, Wendy DO1; Zikos, Thomas MD2; Neshatian, Leila MD3; Nguyen, Linda MD3. S0476 High Prevalence of Methane Predominant Small Bowel Bacterial Overgrowth and Constipation in Patients With Hypermobile Ehlers-Danlos Syndrome. The American Journal of Gastroenterology: October 2020 - Volume 115 - Issue - p S238 doi: 10.14309/01.ajg.0000703952.17443.b0


Edited by Yufan Lu, student of Joan Slonczewski for BIOL 116 Information in Living Systems, 2022, Kenyon College.

Retrieved from "https://microbewiki.kenyon.edu/index.php?title=Small_Intestinal_Bacterial_Overgrowth&oldid=157740"